




US 20120041480A1

(19) **United States**(12) **Patent Application Publication**
Abbott et al.(10) **Pub. No.: US 2012/0041480 A1**(43) **Pub. Date: Feb. 16, 2012**(54) **SYSTEMS AND METHODS FOR TREATING
SEPTAL DEFECTS**(76) Inventors: **Ryan Abbott**, San Jose, CA (US);
W. Martin Belef, San Jose, CA
(US); **Dean Carson**, Mountain
View, CA (US); **Rajiv Doshi**,
Stanford, CA (US); **Richard S.**
Ginn, San Jose, CA (US); **Ronald**
J. Jabba, Redwood City, CA (US);
William A. Gray, Mercer Island,
WA (US)10/734,670, filed on Dec. 11, 2003, now Pat. No.
8,070,826, which is a division of application No.
09/948,453, filed on Sep. 7, 2001, now Pat. No. 6,702,
835, which is a continuation-in-part of application No.
09/948,502, filed on Sep. 6, 2001, now Pat. No. 6,776,
784.**Publication Classification**(51) **Int. Cl.**
A61B 17/10 (2006.01)(52) **U.S. Cl.** **606/213**(21) Appl. No.: **13/282,392**(22) Filed: **Oct. 26, 2011****Related U.S. Application Data**(60) Continuation of application No. 12/260,932, filed on
Oct. 29, 2008, which is a division of application No.
11/175,814, filed on Jul. 5, 2005, now abandoned,
which is a continuation-in-part of application No.
10/847,747, filed on May 17, 2004, now abandoned,
which is a continuation-in-part of application No.(57) **ABSTRACT**

A system for treating a septal defect having an implantable treatment apparatus and devices for delivering the implantable treatment apparatus and methods for treating a septal defect are provided. The implantable treatment apparatus is preferably implantable through a septal wall or portion thereof. The treatment system can include a flexible elongate body member, a delivery device configured to deliver the implantable apparatus, a stabilization device configured to stabilize the body member and a positioning device configured to position the delivery device in a desired location.






FIG. 1






FIG. 2A






FIG. 2D




FIG. 3




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F




FIG. 4G




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D







FIG. 5E








FIG. 6G




FIG. 6H








FIG. 6I








FIG. 8






FIG. 9A






FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 11C

FIG. 12




FIG. 13




FIG. 14A







FIG. 14B














FIG. 14F






FIG. 16A




FIG. 16B




FIG. 16C




FIG. 17




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 19A




FIG. 19B




FIG. 20A




FIG. 20B




FIG. 21









FIG. 22








FIG. 25A




FIG. 25B




FIG. 25C




FIG. 25D




FIG. 26A




FIG. 26B




FIG. 26C




FIG. 27A




FIG. 27B




FIG. 28A




FIG. 28B




FIG. 28C






FIG. 28D






FIG. 29C








FIG. 30






FIG. 32D




FIG. 33A




FIG. 33B




FIG. 34A




FIG. 34B




FIG. 34C




FIG. 35A




FIG. 35B




FIG. 36A




FIG. 36B




FIG. 37A




FIG. 37B




FIG. 38A




FIG. 38B




FIG. 38C




FIG. 38D







FIG. 38E





*FIG. 40*

SYSTEMS AND METHODS FOR TREATING SEPTAL DEFECTS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. patent application Ser. No. 12/260,932, filed Oct. 29, 2008, which is a divisional of U.S. patent application Ser. No. 11/175,814, filed Jul. 5, 2005, now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 10/847,747, filed on May 7, 2004, now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 10/734,670, filed Dec. 11, 2003, which is a divisional of Ser. No. 09/948,453, filed Sep. 7, 2001, now U.S. Pat. No. 6,702,835, which is a continuation-in-part of Ser. No. 09/948,502, filed Sep. 6, 2001, now U.S. Pat. No. 6,776,784, all of which are fully incorporated herein by reference.

FIELD OF THE INVENTION

[0002] The present invention relates generally to systems and methods for closing internal tissue defects, and more particularly to systems and methods for closing a patent foramen ovale or other septal defect.

BACKGROUND OF THE INVENTION

[0003] By nature of their location, the treatment of internal tissue defects is inherently difficult. Access to a defect through invasive surgery introduces a high level of risk that can result in serious complications for the patient. Access to the defect remotely with a catheter or equivalent device is less risky, but treatment of the defect itself is made more difficult given the limited physical abilities of the catheter. The difficulty in accessing and treating tissue defects is compounded when the defect is found in or near a vital organ. For instance, a patent foramen ovale ("PFO") is a serious septal defect that can occur between the left and right atria of the heart and a patent ductus arteriosus ("PDA") is an abnormal shunt between the aorta and pulmonary artery.

[0004] During development of a fetus in utero, oxygen is transferred from maternal blood to fetal blood through complex interactions between the developing fetal vasculature and the mother's placenta. During this process, blood is oxygenated within the fetal lungs. In fact, most of the fetus' circulation is shunted away from the lungs through specialized vessels and foramina that are open during fetal life, but typically closed shortly after birth. Occasionally, however, these foramina fail to close and create hemodynamic problems, which, in extreme cases, can ultimately prove fatal. During fetal life, an opening called the foramen ovale allows blood to pass directly from the right atrium to the left atrium (bypassing the lungs). Thus, blood that is oxygenated via gas exchange with the placenta may travel through the vena cava into the right atrium, through the foramen ovale into the left atrium, and from there into the left ventricle for delivery to the fetal systemic circulation. After birth, with pulmonary circulation established, the increased left atrial blood flow and pressure causes the functional closure of the foramen ovale and, as the heart continues to develop, this closure allows the foramen ovale to grow completely sealed.

[0005] In some cases, however, the foramen ovale fails to close entirely. This condition, known as a PFO, can allow blood to continue to shunt between the left and right atria of the heart throughout the adult life of the individual. PFO's can

pose serious health risks for the individual, including strokes and migraines. The presence of PFO's have been implicated as a possible contributing factor in the pathogenesis of migraine. Two current hypothesis that link PFO's with migraine include the transit of vasoactive substances or thrombus/emboli from the venous circulation directly into the left atrium without passing through the lungs where they would normally be deactivated or filtered respectively. Other diseases that have been associated with PFO's (and which could benefit from PFO closure) include but are not limited to depression and affective disorders, personality and anxiety disorders, pain stroke, TIA, dementia, epilepsy, and sleep disorders.

[0006] Still other septal defects can occur between the various chambers of the heart, such as atrial-septal defects (ASD's), ventricular-septal defects (VSD's), and the like. To treat these defects as well as PFO's, open heart surgery can be performed to ligate and close the defect. Alternatively, catheter-based procedures have been developed that require introducing umbrella or disc-like devices into the heart. These devices include opposing expandable structures connected by a hub or waist. Generally, in an attempt to close the defect, the device is inserted through the natural opening of the defect and the expandable structures are deployed on either side of the septum to secure the tissue surrounding the defect between the umbrella or disc-like structure.

[0007] These devices suffer from numerous shortcomings. For instance, these devices typically involve frame structures that often support membranes, either of which may fail during the life of the patient, thereby introducing the risk that the defect may reopen or that portions of the device could be released within the patient's heart. These devices can fail to form a perfect seal of the septal defect, allowing blood to continue to shunt through the defect. Also, the size and expansive nature of these devices makes safe withdrawal from the patient difficult in instances where withdrawal becomes necessary. The presence of these devices within the heart typically requires the patient to use anti-coagulant drugs for prolonged periods of time, thereby introducing additional health risks to the patient. Furthermore, these devices can come into contact with other portions of the heart tissue and cause undesirable side effects such as an arrhythmia, local tissue damage, and perforation.

[0008] Accordingly, improved systems and methods for closing internal tissue defects within the heart are needed.

SUMMARY

[0009] Improved systems and methods for closing internal tissue defects, such as septal defects and the like, are provided herein by the way of exemplary embodiments. These embodiments are examples only and are not intended to limit the invention.

[0010] In one exemplary embodiment, an implantable apparatus for treating a septal defect is provided having a body with a first end portion, a second end portion and a central portion located therebetween. Preferably, the first end portion is configured to engage a first septal surface, the second end portion is configured to engage a second septal surface and the central portion is configured to fit within an opening in a septal wall.

[0011] In another exemplary embodiment, a treatment system is provided having a first elongate member and a second elongate delivery member having a distal end rotatably coupled with the first elongate member, wherein the orienta-

tion of the distal end is adjustable from a first orientation to a second orientation upon advancement of the elongate member in a distal direction.

[0012] In another exemplary embodiment, a treatment system is provided having an elongate tubular member having an inner lumen configured to slidably receive and interact with an inner elongate member. Preferably, the inner elongate member is configured to deploy a grasping device through an aperture in the elongate tubular member upon movement of the elongate inner member with respect to the elongate tubular member.

[0013] In yet another exemplary embodiment, a treatment system is provided having a flexible positioning member having a distal end and an elongate support member having an inner lumen configured to slidably receive the flexible positioning member. Preferably, the inner lumen has a distal end configured to abut the distal end of the flexible positioning member and an open portion located proximal to the distal end of the lumen. The flexible positioning member is also preferably configured to extend from the open portion upon advancement of the flexible positioning member distally against the distal end of the inner lumen.

[0014] In another exemplary embodiment, a method of treating a septal defect is provided, the method including abutting a limbus of a septum secundum with an abutment of a medical device, creating a hole in the septum secundum with the limbus as a point of reference, and using the hole to facilitate delivery of a device configured to treat a septal defect.

[0015] In another exemplary embodiment, a treatment system is provided having an implantable treatment device, a flexible elongate delivery device configured to deliver the implantable treatment device, a stabilization device insertable within an opening in a septum, or tunnel between two septa, and configured to stabilize an elongate body member, and the elongate body member configured for insertion within the vasculature of a patient, the body member configured to slidably receive the delivery device and stabilization device.

[0016] Other systems, methods, features and advantages of the invention will be or will become apparent to one with skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features and advantages be included within this description, be within the scope of the invention, and be protected by the accompanying claims. It is also intended that the invention is not limited to require the details of the example embodiments.

BRIEF DESCRIPTION OF THE FIGURES

[0017] The details of the invention, both as to its structure and operation, may be gleaned in part by study of the accompanying figures, in which like reference numerals refer to like parts. The components in the figures are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention. Moreover, all illustrations are intended to convey concepts, where relative sizes, shapes and other detailed attributes may be illustrated schematically rather than literally or precisely.

[0018] FIG. 1 is a block diagram depicting an exemplary embodiment of a treatment system.

[0019] FIG. 2A is an exterior/interior view of the right atrium depicting an example human heart.

[0020] FIGS. 2B-2C are enlarged views of an example arterial septal wall.

[0021] FIG. 2D is a cross-sectional view taken along line 2D-2D of FIGS. 2B-2C depicting another example septal wall.

[0022] FIG. 3 is a block diagram depicting an exemplary embodiment of an implantable treatment device.

[0023] FIG. 4A is a perspective view depicting another exemplary embodiment of an implantable treatment device.

[0024] FIG. 4B is a perspective view depicting an exemplary embodiment of several coiled segments of an implantable treatment device.

[0025] FIG. 4C depicts a side view of the embodiment of the implantable treatment device taken along direction 330 of FIG. 4A.

[0026] FIG. 4D is a schematic view depicting another exemplary embodiment of the implantable treatment device as viewed from direction 329 of FIG. 4C.

[0027] FIG. 4E is cross-sectional view depicting the exemplary embodiment of the implantable treatment device depicted in FIG. 4A implanted within an example heart.

[0028] FIGS. 4F-G are cross-sectional views of additional exemplary embodiments of the treatment system with a delivery device.

[0029] FIGS. 5A-E are perspective views depicting additional exemplary embodiments of the central portion the implantable treatment device.

[0030] FIGS. 6A-I are perspective views depicting additional exemplary embodiments of either the first and/or the second end portions of the implantable treatment device.

[0031] FIG. 7A-C, 8 and 9A-C are perspective views depicting additional exemplary embodiments of the implantable treatment device.

[0032] FIG. 10A is a flow diagram depicting one exemplary method of manufacturing another exemplary embodiment of the implantable treatment device.

[0033] FIG. 10B is a perspective view of an exemplary embodiment of a body shaping device.

[0034] FIGS. 11A-B is a perspective view depicting another exemplary embodiment of an implantable treatment device.

[0035] FIG. 12 depicts another exemplary embodiment of the treatment system within a heart.

[0036] FIG. 13 is a block diagram depicting an exemplary embodiment of a delivery device.

[0037] FIG. 14A is a perspective view depicting another exemplary embodiment of the treatment system.

[0038] FIG. 14B is a cross-sectional view depicting another exemplary embodiment of the delivery device.

[0039] FIGS. 14C-F are perspective views depicting a portion of the septal wall and an additional exemplary embodiment of the treatment system.

[0040] FIGS. 15A-D are perspective views depicting additional exemplary embodiments of the delivery device.

[0041] FIGS. 16A-B are cross-sectional views depicting additional exemplary embodiments of the treatment system.

[0042] FIG. 16C is a perspective view depicting the embodiment described with respect to FIGS. 16A-B during delivery.

[0043] FIG. 17 is a cross-sectional view depicting an exemplary embodiment of the delivery device taken along line 17-17 of FIG. 14A.

[0044] FIG. 18A is a cross-sectional view of an exemplary embodiment of a needle member.

[0045] FIGS. 18B-C are cross-sectional views depicting additional exemplary embodiments of a delivery device.

[0046] FIGS. 19A-B are cross-sectional views depicting exemplary embodiments of a delivery device and an implantable treatment device.

[0047] FIGS. 20A-B are schematic views depicting additional exemplary embodiments of a delivery device and an implantable treatment device.

[0048] FIG. 21 is a cross-sectional view depicting another exemplary embodiment of a delivery device taken along lines 21-21 of FIG. 14A.

[0049] FIG. 22 is a block diagram depicting an exemplary embodiment of a stabilization device.

[0050] FIGS. 23A-C are cross-sectional views depicting additional exemplary embodiments of a stabilization device.

[0051] FIGS. 24A-B are perspective views depicting additional exemplary embodiments of a stabilization device.

[0052] FIGS. 25A-D are cross-sectional views depicting additional exemplary embodiments of a stabilization device.

[0053] FIGS. 26A-C are cross-sectional views depicting additional exemplary embodiments of a stabilization device.

[0054] FIG. 27A is a perspective view depicting an additional exemplary embodiment of a stabilization device.

[0055] FIG. 27B is a cross-sectional view depicting another exemplary embodiment of a stabilization device.

[0056] FIGS. 28A-C are cross-sectional views depicting additional exemplary embodiments of a centering device.

[0057] FIG. 28D is a schematic view depicting another exemplary embodiment of a centering device within a septal wall.

[0058] FIGS. 29A-C, 30 and 31 are schematic views depicting additional exemplary embodiments of a centering device.

[0059] FIGS. 32A-B are cross-sectional views depicting additional exemplary embodiments of a centering device.

[0060] FIG. 32C is a cross-sectional view depicting another exemplary embodiment of a centering device with an exemplary embodiment of a stabilization device.

[0061] FIG. 32D is a schematic view depicting another exemplary embodiment of a centering device with an exemplary embodiment of a stabilization device.

[0062] FIG. 33A is a longitudinal cross-sectional view of an exemplary embodiment of a treatment system.

[0063] FIG. 33B is a radial cross-sectional view of another exemplary embodiment of a treatment system taken along line 33B-33B of FIG. 33A.

[0064] FIG. 34A is a longitudinal cross-sectional view of an exemplary embodiment of a treatment system.

[0065] FIG. 34B is a radial cross-sectional view of another exemplary embodiment of a treatment system taken along line 34B-34B of FIG. 34A.

[0066] FIG. 34C is a longitudinal cross-sectional view of another exemplary embodiment of a treatment system taken along line 34C-34C of FIG. 34A.

[0067] FIG. 35A is a longitudinal cross-sectional view of an exemplary embodiment of a treatment system.

[0068] FIG. 35B is a radial cross-sectional view of another exemplary embodiment of a treatment system taken along line 35B-35B of FIG. 35A.

[0069] FIG. 36A is a longitudinal cross-sectional view of an exemplary embodiment of a treatment system.

[0070] FIG. 36B is a radial cross-sectional view of another exemplary embodiment of a treatment system taken along line 36B-36B of FIG. 36A.

[0071] FIG. 37A is a longitudinal cross-sectional view of an exemplary embodiment of a treatment system.

[0072] FIG. 37B is a radial cross-sectional view of another exemplary embodiment of a treatment system taken along line 37B-37B of FIG. 37A.

[0073] FIGS. 38A-E are cross-sectional views of a septal wall depicting exemplary embodiments of the implantable treatment device.

[0074] FIGS. 39A-B are flow diagrams depicting an example of a method of treating a septal defect.

[0075] FIG. 40 is a flow diagram depicting another exemplary method of treating a septal defect.

DETAILED DESCRIPTION

[0076] Described herein are improved devices and methods for treating septal defects. For ease of discussion, the devices and methods will be described with reference to treatment of a PFO. However, it should be understood that the devices and methods can be used in treatment of any type of septal defect including ASD's, VSD's and the like, as well as PDA's or other structural cardiac or vascular defects.

[0077] FIG. 1 is a block diagram depicting a distal portion of an exemplary embodiment of a septal defect treatment system 100 configured to treat, and, preferably close, a PFO. In this embodiment, treatment system 100 includes an elongate body member 101 configured for insertion into the vasculature of a patient (human or animal) having a septal defect. Body member 101 has a longitudinal axis 107 and can include one or more lumens 102, each of which can be configured for achieving multiple functions. Preferably, treatment system 100 includes an implantable device 103 (referred to herein as an "implant") configured to at least partially close a septal defect. Treatment system 100 can include a flexible elongate delivery device 104 configured to house and deliver implant 103. To minimize the width of body member 101, implant 103 can be deformable from the configuration desired after implantation to a configuration having a smaller cross-section for storage and housing within delivery device 104 prior to implantation.

[0078] Treatment system 100 can also optionally include a stabilization device 105 for stabilization of body member 101 during delivery of implant 103 and a centering device 106 for facilitating the centering or the otherwise desired positioning of implant 103 for delivery. Although shown here as four separate components, any combination of body member 101, delivery device 104, stabilization device 105 and centering device 106 can be integrated together to reduce the number of components to three, two or one total components in treatment system 100.

[0079] To better understand the many alternative embodiments of treatment system 100, the anatomical structure of an example human heart having a PFO will be described in brief. FIG. 2A is an exterior/interior view depicting an example human heart 200 with a portion of the inferior vena cava 202 and the superior vena cava 203 connected thereto. Outer tissue surface 204 of heart 200 is shown along with the interior of right atrium 205 via cutaway portion 201. Depicted within right atrium 205 is septal wall 207, which is placed between right atrium 205 and the left atrium located on the opposite side (not shown). Also depicted is fossa ovalis 208, which is a region of septal wall 207 where the tissue is relatively thinner than the surrounding tissue. PFO region 209 is located near the upper portion beyond the fossa ovalis 208.

[0080] FIG. 2B is an enlarged view of septal wall 207 depicting PFO region 209 in more detail as viewed from right atrium 205. PFO region 209 includes septum secundum 210, which is a first flap-like portion of septal wall 207. The edge of this flap above fossa ovalis 208 is referred to as the limbus 211. FIG. 2C is also an enlarged perspective view of septal wall 207, instead depicting septal wall 207 as viewed from left atrium 212. Here, PFO region 209 is seen to include septum primum 214, which is a second flap-like portion of septal wall 207. Septum primum 214 and septum secundum 210 partially overlap each other and define a tunnel-like opening 215 between sidewalls 219 (indicated as dashed lines in FIGS. 2B-C) that can allow blood to shunt between right atrium 205 and left atrium 212 and is commonly referred to as a PFO.

[0081] FIG. 2D is a cross-sectional view depicting an example PFO region 209 taken along line 2D-2D of FIGS. 2B-C. Here, it can be seen that septum secundum 210 is thicker than septum primum 214. Typically, the blood pressure within left atrium 212 is higher than that within right atrium 205 and tunnel 215 remains sealed. However, under some circumstances a valsalva condition can occur where the blood pressure within right atrium 205 becomes higher than the blood pressure within left atrium 212 and blood shunts from right atrium 205 to left atrium 212. Because most typical shunts occur in this manner and for purposes of facilitating the discussion herein, region 217 in FIG. 2D will be referred to as PFO entrance 217, and region 218 will be referred to as PFO exit 218.

[0082] Many different variations of PFO's can occur. For instance, thickness 220 of septum primum 214, thickness 221 of septum secundum 210, overlap distance 222 and the flexibility and distensibility of both septum primum 214 and septum secundum 210 can all vary. In FIGS. 2B-C, PFO entrance 217 and PFO exit 218 are depicted as being relatively the same size with the width of tunnel 215, or the distance between sidewalls 219, remaining relatively constant. However, in some cases PFO entrance 217 can be larger than PFO exit 218, resulting in an tunnel 215 that converges as blood passes through. Conversely, PFO entrance 217 can be smaller than PFO exit 218, resulting in an opening that diverges as blood passes through. Furthermore, multiple PFO entrances 217 and multiple PFO exits 218 can be present, with one or more individual openings 215 therebetween. Also, in FIGS. 2B-D, both septum primum 214 and septum secundum 210 are depicted as relatively planar tissue flaps, but in some cases one or both of septum primum 214 and septum secundum 210 can have folded, non-planar, highly irregular shapes.

[0083] As will be described in more detail below, treatment of a PFO preferably includes inserting treatment system 100 into the vasculature of a patient and advancing body member 101 through the vasculature to inferior vena cava 202, from which access to right atrium 205 can be obtained. Once properly positioned within right atrium 205, delivery device 104 can be used to deliver implant 103 to PFO region 209, preferably by inserting implant 103 through septum secundum 210 and primum 214 such that implant 103 lies transverse to tunnel 215 and can at least partially close tunnel 215.

[0084] FIG. 3 is a block diagram depicting one exemplary embodiment of implant 103. Implant 103 can be configured in an almost limitless number of different ways, as this block diagram shows. Here, implant 103 includes a first end portion 301, a second end portion 302 and a central portion 303

preferably coupled therebetween. First and second end portions 301-302 are each preferably configured to engage opposing surfaces of septal wall 207. First end portion 301 can be configured to engage the surface of septal wall 207 on the right atrium (RA) side, while second end portion can be configured to engage the surface of septal wall 207 on the left atrium (LA) side. Although end portions 301-302 can be placed anywhere within heart 200 as desired, in order to facilitate the description of implant 103 herein, first end portion 301 will be referred to as RA portion 301 and second end portion will be referred to as LA portion 302.

[0085] Central portion 303 is preferably configured to fit within a manmade or surgically created opening in either septum primum 214, septum secundum 210 or both. Central portion 303 is also preferably configured to apply a force adequate to bring end portions 301-302 towards one another when implanted, to be implantable into septal walls 207 of varying thickness and to fit within elongate body member 101, the diameter of which is preferably minimized for ease of insertion within the patient's vasculature.

[0086] Implant 103 can be configured in any manner desired to fit the needs of the application. Implant 103 can have any size and shape and can include additional portions not shown in FIG. 3 to achieve a different set of functions. Implant 103 can also be fabricated in any desired manner and from any materials suitable for implantation within the patient including, but not limited to, elastic materials, super-elastic materials, shape-memory materials, composite materials, polymeric materials and biodegradable materials.

[0087] FIG. 4A is a perspective view depicting another exemplary embodiment of implant 103 shown in an "at rest" configuration. In this embodiment, implant 103 is configured in a coil-shaped manner with a wire-like body 304 composed of an elastic material. Wire-like body 304 can have any wire-like cross-sectional shape including, but not limited to circular, elliptical, oval, rounded, arcuate, polygonal and any combination thereof. Each portion 301-303 can be composed of one or more coiled segments 306, with a coiled segment 306 being defined herein as a segment that is curved in any manner about one or more axes. A coiled segment 306 can be curved less than 360 degrees about the one or more axes. FIG. 4B is a perspective view depicting an exemplary embodiment of several coiled segments 306, which could be used in any of portions 301-303. In this embodiment, each coiled segment 306 is coiled with a constant rate of curvature about the same axis 309. Coiled segments 306 have approximately the same width 310 and are stacked and separated by a distance 311, which will be referred to herein as stacking distance 311.

[0088] Referring back to FIG. 4A, implant 103 has an overall width 336. Central portion 303 includes a plurality of coiled segments 306 having substantially the same width 310. Each end portion 301-302 includes a plurality of coiled segments having varied widths 310. In this case, the width 310 of the outermost coiled segment 306 is the greatest and the widths 310 of each successive coiled segment 306 decreases as one approaches the innermost coiled segment 306. Each end portion 301-302 is coupled with central portion 303 via optional generally straight sections 305. Generally straight sections 305 can prevent blood from shunting between the right and left atria through open interior region 327 of coiled central portion 303, by allowing the adjacent tissue to encroach upon and surround straight section 305. Plugs of bioabsorbable or hydrophilic material may also be provided to minimize such shunting. Generally straight sections 305

can also prevent tissue from getting caught, or hung up, between central portion **303** and RA/LA portions **301/302**. Each generally straight sections **305** is not required to be straight and, in fact, can have any non-coiled shape. Central portion **303** can be placed approximately equidistant from end portions **301-302**, as depicted here, or central portion **303** can be placed closer to one of end portions **301-302** than the other. Generally straight sections **305** are optional and can be included on only one side of central portion **303** or omitted altogether, in which case the coiled segments **306** of central portion **303** extend directly up to a coiled segment **306** of each end portion **301-302**.

[0089] The end tips **307** of body **304** are preferably atraumatic so as to minimize injury to cardiac tissue. In this embodiment, end tips **307** are rounded and have a larger diameter than body **304**. End tips **307** can also be configured as floppy tips that are curled or coiled and can be flexible or non-flexible. Also, it should be noted that any part of implant **103** can be modified for imaging purposes. For instance, in this embodiment end tips **307** are radio-opaque to increase visibility of implant **103** during imaging.

[0090] FIG. 4C depicts a side view of the embodiment of implant **303** taken along direction **330** of FIG. 4A. For ease of illustration, FIG. 4C depicts only the outermost coiled segment **306** of RA portion **301**, transition section **331** and the generally straight section **305** located between RA portion **301** and central portion **303**. Transition section **331** is an optional section of implant **103** that can be straight, curved or any other shape. FIG. 4D depicts RA portion **301**, transition section **331** and the generally straight section **305** located between RA portion **301** and central portion **303** as viewed from direction **329** of FIG. 4C. Here, it can be seen that transition section **331** connects to generally straight section **305** at 90 degree angle **332**. Angle **332** can be varied as desired, but values of angle **332** approaching 0 degrees or 180 degrees are less preferable due to the increased risk of RA portion **301** (or LA portion **302**) being drawn into manmade opening **315**, which is described in more detail below.

[0091] FIG. 4E is cross-sectional view depicting the exemplary embodiment of implant **103** depicted in FIG. 4A implanted within heart **200** using one exemplary method of implantation. Here, an opening **315** has been surgically created in septum primum **214** and septum secundum **210** and implant **103** has been positioned such that central portion **303** resides within the opening **315**. RA portion **301** and LA portion **302** are positioned on opposite sides of septal wall **207** to engage surface **320** of septum secundum **210** and surface **321** of septum primum **214**, respectively. Central portion **303** preferably exerts a contractile force **312** to bring portions **301-302** towards one another, which in turn preferably draws septum primum **214** and septum secundum **210** together to at least partially close PFO tunnel **215**. As mentioned above, the widths **310** of coiled segments **306** of RA and LA portions **301-302** get progressively larger from the innermost to the outermost segment **306**. If the rate of change of width **310** is large enough to allow coiled segments **306** to pass through each other, then portions **301** and **302** can exert additional closure forces **313** and **314**, respectively, which oppose each other and assist central portion **303** in closing PFO tunnel **215**.

[0092] LA portion **302** and RA portion **301** can each be sized in any manner desired. Preferably, LA portion **302** is configured to have relatively larger coiled segment widths **310**, include relatively more coiled segments **306** and exert a

closure force over a relatively larger area **314** than RA portion **301**. This can be for one of at least two reasons. As will be described in more detail below, preferably, LA portion **302** is deployed in PFO region **209** first and, once in contact with septal wall **207**, LA portion **302** is used to help deploy, or pull, portions **303** and **301** from delivery device **104**. Also, septum primum **214** is typically thinner than septum secundum **210** and more likely to tear or deform to the extent that LA portion **302** can be pulled through septum primum **214**.

[0093] Preferably, implant **103** is configured to adjust to septal walls **207** having varying degrees of thickness. Accordingly, central portion **303** preferably has a compressibility sufficient to apply a closure force **312** to thinner septal walls **207** while at the same time having an expandability sufficient to accommodate thicker septal walls **207** without becoming permanently deformed. In one exemplary embodiment, which is for purposes of illustration only and should not be used to limit the scope of the invention in any way, central portion **303** is expandable from 3 to 8 millimeters (mm) without becoming excessively permanently deformed.

[0094] As mentioned above, implant **103** can be deformable between a configuration suited for housing within delivery device **104** and the implanted configuration depicted in FIG. 4E. FIG. 4F is a cross-sectional view of an exemplary embodiment of treatment system **100** depicting delivery device **104** having an inner lumen **402** with implant **103** housed therein. Implant **103** is preferably housed within lumen **402** until body member **101** is advanced within the patient into the desired position within heart **200** for implantation, at which time implant **103** is delivered to PFO region **209** through open distal end **403**. Here, implant **103** is deformed from the at rest, i.e., unbiased, configuration depicted in FIG. 4A into a generally straight configuration where coiled portions **301-303** are mostly unwound into a relatively straight state. This housed configuration significantly reduces the overall width **336** of implant **103** and allows the size of delivery device **104** and, in turn, body member **101** to be minimized.

[0095] FIG. 4G is a cross-sectional view of another exemplary embodiment of treatment system **100** depicting delivery device **104** with implant **103** in the housed configuration. Here, central portion **303** of implant **103** remains coiled in a state similar to the resting state of FIG. 4A, while RA/LA portions **301/302** are partially unwound into a relatively straight state from the coiled rest state. Preferably, coiled segments **306** of central portion **303** generally have smaller widths **310** than most of the coiled segments **306** of RA/LA portions **301/302**. Coiled segments **306** having a smaller width, i.e., more tightly wound coils, can be permanently deformed more easily when unwound and, therefore, by maintaining central portion **303** in the coiled state, the risk of permanent deformation to central portion **303** is reduced. Implant **103** can be deformed in any manner when housed within delivery device **104**. For coil-like embodiments of implant **103**, this can include deforming any or all of coiled segments **306**, to any degree, in any portion **301-303**.

[0096] To facilitate the deformation of implant **103** between the housed configuration and the implanted configuration depicted in FIG. 4E, implant **103** is preferably composed of an elastic material. Preferably, body **304** is composed of a titanium-nickel alloy such as NITINOL, although any elastic material can be used, including polymers, rubber-like materials, stainless steel, other metal alloys and the like. As one of skill in the art will recognize, the amount of closure

force **312-314**, the degree of allowable deformation and the like will depend, in part, on the type of material used to form body **304**.

[0097] FIGS. 5A-E are perspective views depicting additional exemplary embodiments of central portion **303** of implant **103**. Each of these embodiments can be used with any RA portion **301** and LA portion **302**. In FIG. 5A, central portion **303** includes a plurality of coiled segments **306** where the stacking distance **311** between each segment **306** is relatively greater than the embodiment of central portion **303** depicted in FIG. 5B. Generally, a smaller stacking distance **311** will provide a greater closure force **312**, if all other implant parameters remain the same. Any stacking distance **311** can be used in central portion **303** as desired, including configurations where there is no gap between each coiled segment **306**, i.e., each coiled segment **306** lies flush with any adjacent coiled segment **306**. Use of a larger stacking distance **311** that provides for gaps between adjacent coiled segments **306** allows the adjacent septal tissue to grow into the open interior region **327** of the coiled central portion **303**, which can provide positional stability to the device, reduce immune reactions to the device and reduce any risk of blood shunting through open region **327**.

[0098] In FIG. 5C, central portion **303** includes a combination of coiled sections **324** and generally straight sections **305**. It should be noted that central portion **303** can include any number of one or more coiled sections **324** in any combination with any number of one or more generally straight sections **305**. As can be seen here, each coiled section **324** can be configured differently from any other coiled section **324**, i.e., each coiled portion can include a different number of coiled segments **306**, with different stacking distances **311** and different widths **310**, etc.

[0099] FIG. 5D depicts another exemplary embodiment where blocking material **326** has been coupled with coil body **304**. Blocking material **326** preferably reduces any risk of blood shunting through the interior of coiled segments **306**, either by blocking blood flow directly or by facilitating the formation of blood clots within open interior region **327**. In one exemplary embodiment, blocking material **326** can include multiple DACRON fibers adhesively or mechanically coupled to the outer surface of body **304**. In another exemplary embodiment, a polymer or metal plug is placed in open interior region **327** to prevent blood flow. As one of skill in the art will readily recognize, any type of plug, device, material or coating can be used and attached to body **304** in any manner, the numerous combinations of which will not be listed here.

[0100] Central portion **303** is not required to include a coiled section **324** and can, in fact, be only a generally straight section **305**. Furthermore, central portion **304** is not required to be formed from a wire-like body **304** and can be configured in any manner desired as depicted in the block diagram of FIG. 3. For instance, central portion **303** can be formed from an elastomeric or rubber-like stretchable member, as depicted in FIG. 5E.

[0101] Referring in more detail to RA portion **301** and LA portion **302**, FIGS. 6A-I are perspective views depicting multiple embodiments exemplary of either RA portion **301** or LA portion **302**. Any of the RA/LA portions **301/302** depicted here can be used with any embodiment of central portion **303** described with respect to FIGS. 5A-E. For instance, an exemplary embodiment of implant **103** can have RA portion **301** configured in a manner similar to that described with respect to FIG. 6A, central portion **303** configured in a manner similar

to that described with respect to FIG. 5A, and RA portion **301** configured in a manner similar to that described with respect to FIG. 6B.

[0102] In FIG. 4A, RA/LA portions **301/302** include multiple stacked coiled segments **306** having gradually decreasing widths **310** from the outermost to the innermost segment **306**. In FIG. 6A, RA/LA portions **301/302** include multiple coiled segments **306** having gradually increasing widths **310** from the outermost to the innermost segment **306**. The embodiment of portions **301-302** described with respect to FIG. 4A can be less susceptible to entering opening **315**, due to the presence of a relatively larger coiled segment **306** coupled with transition region **305**.

[0103] In both FIGS. 4A and 6A, coiled segments **306** of RA/LA portions **301/302** are stacked in an inwards manner, i.e., the outermost segment **306** is coupled with central portion **303** or generally straight section **305**, if present (as shown here) and RA/LA portion **301/302** overlaps central portion **303**. In FIGS. 6B-C, RA/LA portions **301/302** include multiple coiled segments **306** stacked in an outwards manner, i.e., the innermost segment **306** is coupled with central portion **303** or generally straight section **305**, if present (as shown here). Generally, stacking segments **306** in an inwards manner will provide greater closure forces than stacking in an outwards manner. In FIG. 6B, RA/LA portions **301/302** include multiple coiled segments **306** having gradually increasing widths **310** from the outermost to the innermost segment **306**, while in FIG. 6C, RA/LA portions **301/302** include multiple coiled segments **306** having gradually decreasing widths **310** from the outermost to the innermost segment **306**.

[0104] In FIG. 6D, RA/LA portions **301/302** are tightly stacked with a constant width **310** such that no gap exists between adjacent coiled segments **306**. This embodiment of RA/LA portions **301/302** exhibits a high resistance to the potential for being pulled into opening **315**.

[0105] RA/LA portions **301/302** are not required to be implemented in a stacked configuration. For instance, in FIGS. 6E-F, RA/LA portions **301/302** each include multiple coiled segments **306** having varying widths **310** arranged in a generally co-planar fashion, i.e., for all segments **306** the stacking distance **311** is close to or equal to zero. In FIG. 6E, the smallest coiled segment **306** is coupled with generally straight section **305**, while in FIG. 6F, the largest coiled segment **306** is coupled with generally straight section **305**. To lessen the risk of RA/LA portions **301/302** being pulled into opening **315** in the embodiment depicted in FIG. 6F, transition section **329** is preferably positioned on the outside of coiled segments **306** such that, when implanted, coiled segments **306** are located between transition section **329** and septal wall **327**.

[0106] In the embodiments discussed above, the radius of curvature of the coiled segments **306**, present in either RA/LA portions **301/302** or central portion **303**, is generally constant or varies at a constant rate, resulting in a circular, spiral or helical appearance when viewed from the side (e.g., direction **330** of FIG. 4A). It should be understood that the radius of curvature can vary at any rate, abruptly or gradual, allowing coiled segments **306** to take any shape or form desired, whether in RA/LA portions **301/302** or central portion **303**. For instance, FIGS. 6G-H are schematic views depicting additional exemplary embodiments of RA/LA portions **301/302** as viewed from the side. FIG. 6G depicts RA/LA portion **301/302** having an elliptical D shape. Here, RA/LA portion

301/302 has an elliptical portion **334** and a generally straight portion **335**, which can be placed adjacent to fossa ovalis **208** to lessen the extent to which RA/LA portion **301/302** overlaps fossa ovalis **208** and minimize the risk of piercing or rupturing fossa ovalis **208**. FIG. 6G depicts another exemplary embodiment of RA/LA portion **301/302** having a generally pentagonal shape.

[0107] RA/LA portions **301/302** are not required to include coiled segments **306** and are not required to be formed from a wire-like body **304**. As mentioned above, RA/LA portions **301/302** can be configured in any manner desired as depicted in the block diagram of FIG. 3. For instance, RA/LA portions **301/302** can be formed from an elastomeric or rubber-like membrane **336** in an umbrella-like fashion, or a sheet-like fashion as depicted in the exemplary embodiment of FIG. 61.

[0108] FIG. 7A-C are perspective views depicting additional exemplary embodiments of implant **103** having a ribbon-like body **304**. Ribbon-like bodies **304** can have a generally polygonal cross-section and can be differentiated from the wire-like bodies **304** depicted in FIGS. 4A-5E, which can have generally circular, rounded etc. cross-sections as described above. FIG. 7A is an embodiment of implant **103** having a ribbon-like body **304** configured similar to that of the embodiment depicted in FIG. 4A. Generally, any of the embodiments described with respect to wire-like bodies **304** can also be implemented with ribbon-like bodies **304**. Ribbon-like bodies **304** can have any ribbon-like cross-sectional shape desired. FIGS. 7B-C are cross-sectional views depicting ribbon-like body **304** having generally polygonal shapes. FIG. 7B is a cross-sectional view depicting ribbon-like body **304** having a generally tapered trapezoidal shape. FIG. 7C is a cross-sectional view depicting ribbon-like body **304** having a generally rectangular shape with rounded corners.

[0109] In addition to other parameters, the thickness of implant body **304** can vary as desired. For instance, FIG. 8 is a perspective view depicting another exemplary embodiment of implant **103** having a wire-like body **304** with varying thicknesses. Here, it can be seen that generally straight section **305** is relatively thicker than the coiled segments **306** of central portion **303**, while interface **333** between generally straight sections **305** and transition sections **329** is relatively thicker still. Relatively thicker regions of body **304**, whether formed from a wire, ribbon or other structure, generally have greater strength and less flexibility than relatively thinner regions of body **304**. Thus, relatively thicker regions can be used to add strength while relatively thinner regions can be used where added flexibility is desired.

[0110] Like the thickness, the surface of body **304** can also be varied as desired. The surface can be modified directly or through etching, grinding, additional coatings or add-ons, which are applied to the underlying body **304**. The surface can be modified for any purpose including, but not limited to increasing surface friction with tissue, increasing the ability to engage tissue, allowing tissue in-growth, promoting healing, promoting scarring, promoting thrombogenicity, preventing blood passage or shunting around or through implant **103**, minimizing thrombus formation, promoting anti-coagulation (e.g., with drugs such as heparin and the like), modifying imaging characteristics (e.g., radio-opacity and the like) and decreasing body surface friction (e.g., with a hydrophilic coating and the like).

[0111] FIGS. 9A-C are perspective views depicting just several additional exemplary embodiments of implant **103** having a modified surface region **340**. The surface of implant

103 can be modified in any location and in any manner desired, including, but not limited to, etching, grinding, coating, drilling, and cutting. For instance, FIGS. 9A-C depict the innermost coiled segment **306** of exemplary embodiments of RA/LA portion **301/302**. In FIG. 9A, wire-like body **304** has been etched or otherwise treated such that modified surface region **340** is a textured surface including multiple recesses **341** for increasing surface friction and allowing coiled segment **306** to more easily grasp septal wall **207**. It should be noted that any surface texture pattern can be used. In FIG. 9B, a coating has been applied to ribbon-like body **304** to create an abrasive surface region **340**, also to increase surface friction. In FIG. 9C, apertures **342** in ribbon-like body **304** are present to facilitate tissue in-growth on and around modified surface region **340**. The use of closely spaced apertures **342** can reduce a body's immune reaction to the presence of implant **103**. Also, in this embodiment the orientation of ribbon-like body **340** has been rotated 90 degrees so that the widest surface is adjacent to the septal tissue.

[0112] As stated above, implant **103** can be configured in any manner desired in accordance with the needs of the application. The following is a non-exhaustive list of just some exemplary factors one of skill in the art may consider in designing, configuring, manufacturing and/or otherwise implementing implant **103**.

[0113] LA portion **302** can be configured to use compressive force **312** from center portion **303** to hold septum primum **214** against septum secundum **210** and at least partially close or seal PFO tunnel **215**. LA portion **302** can also be configured to maintain a stable position as central portion **303** and RA portion **301** are deployed without being pulled through septum primum **210**. LA portion **302** can be configured to lie flush against septum primum **214** when deployed and not to distort the native geometry of tunnel **215** to create residual shunts. LA portion **302** can be sized to provide adequate coverage over PFO tunnel **215**. (In one exemplary embodiment, which is included as an example only and should not be used to limit the invention, LA portion **302** has a maximum width **310** of 1.2 centimeters to accommodate most large PFO tunnels **215**.) LA portion **302**, in combination with central portion **303** and RA portion **301**, can be configured to exert enough closure force **314** to seal PFO tunnel **215** and prevent shunting during normal and valsalva atrial blood pressures. LA portion **302** can also be configured: to be deployable with minimal and consistent push force (e.g., push force on pusher member **406**, which will be described in more detail below); so that the shape before and after deployment is predictable; to be devoid of characteristics that cause chronic or excessive tissue irritation, inflammation, etc.; and/or for visibility during imaging procedures.

[0114] Central portion **303** can be configured to maintain LA portion **302** and RA portion **301** in a state of contact with septal wall **207** with enough closure force **312** to at least partially close and seal PFO tunnel **215**. Central portion **303** can also be configured: with an adequate spring constant (K) to prevent tunnel **215** from opening during normal and valsalva atrial blood pressures; to not distort the native geometry of tunnel **215** and create residual shunts; to be deployable with minimal and consistent push force (e.g., push force on pusher member **406**, which will be described in more detail below); for visibility during imaging procedures; to expand or stretch to accommodate variable septal wall thicknesses without permanent deformation; with adequate strength to withstand any motion it may experience in vivo; to allow LA

portion **302** or RA portion **301** to tilt, for instance, if the area of delivery is wedge shaped; so that central portion **303** does not pinch or sever any tissue that could embolize, for instance, with a spring constant low enough to prevent severing tissue; to exert adequate closure force **212** to close any residual shunts that exist; and/or with maximized width **310** and minimized strains to optimize fatigue performance.

[0115] RA portion **301** can be configured to hold septum secundum **210** against septum primum **214** and at least partially close or seal PFO tunnel **215**. RA portion **301** can also be configured: to lie flush against septum secundum **210** when deployed and not to distort the native geometry of tunnel **215** to create residual shunts; to be deployable with minimal and consistent push force (e.g., push force on pusher member **406**, which will be described in more detail below); so that the shape before and after deployment is predictable; to be devoid of characteristics that cause chronic or excessive tissue irritation, inflammation, etc.; for visibility during imaging procedures; and/or to resist being pulled through septal wall **207**.

[0116] Also provided herein are methods of manufacturing implant **103**. FIG. **10A** is a flow diagram depicting one exemplary method **350** of manufacturing an exemplary embodiment of a coil-like implant **103** having body **304**, which can be wire, ribbon or the like, composed of NITINOL. First, at **351**, a section of NITINOL, from which body **304** can be formed, is pre-processed. Pre-processing **351** can include adding a modified surface region **340** having a desired texture, adjusting body thickness, adjusting the cross-sectional shape of body **304** and the like.

[0117] With a ribbon-like implant **103**, pre-processing can include etching of the NITINOL section. Methods of etching NITINOL materials are readily understood to one of skill in the art. For instance, a sheet of NITINOL is first etched or grinded or otherwise altered to vary the cross-sectional shape, thickness, surface texture and the like of one or more sections present on the sheet. Etching of the NITINOL sheet can allow for the implementation of numerous different cross-sectional shapes, thicknesses, surface textures and combinations thereof. Afterwards, each section of NITINOL can be cut from the sheet and trimmed as desired.

[0118] At **352**, the NITINOL section is fixed to body shaping device **380** in preparation for a heat treatment. Heat treatment of NITINOL can instill the desired at rest configuration to body **304** and is well known to those of skill in the art. Accordingly, body shaping device **380** is preferably shaped such that when the NITINOL section is coiled around body shaping device **380**, it is in the final desired at rest configuration. One exemplary embodiment of body shaping device **380** is depicted in FIG. **10B**. Here, body shaping device **380** is shaped for the exemplary embodiment of implant **103** depicted in FIG. **4A**. Body shaping device **380** includes a central body shaping portion **383** corresponding to the shape of central portion **303**, and two end body shaping portions **381** and **382** corresponding to the shape of RA portion **301** and LA portion **302**, respectively. End body shaping portions **381** and **382** are preferably configured to telescope over central body shaping portion **383** to allow for the inwards manner of coiling of RA/LA portions **301/302** over central portion **303**. Central portion **303** includes recesses **384** into which the NITINOL section can be placed to form generally straight sections **305**. End body shaping portions **381** and **382** also preferably include recess **385** that can allow for each transition section **331**.

[0119] Once wrapped around and fixed to body shaping device **380**, at **353**, the NITINOL section is then preferably heat treated to instill the desired shape. Heat treating can occur at any time and temperature sufficient to instill the desired at rest shape and level of elasticity in implant **103**. In one embodiment, which is included as an example only and should in no way be used to limit the invention, heat treating can occur at a temperature range of 500-550 degrees Celsius for approximately five minutes.

[0120] At **354**, the NITINOL section is preferably cooled, e.g., by rapid quenching in room temperature water, then at **355**, the NITINOL section is preferably removed from body shaping device **380** and end tips **307** are trimmed, if necessary, to the desired length to form body **304**. Finally, at **356**, any post-processing is performed, such as the addition of radio-opaque markers, the shaping of end tips **307** and the addition of any desired coatings or blocking material **326**.

[0121] FIGS. **11A-B** depict additional exemplary embodiments of implant **103**. Specifically, FIG. **11A** is a perspective view depicting an exemplary embodiment of implant **103** formed from a NITINOL tube. In this embodiment, central portion **303** includes multiple coiled segments **306** coupled with RA/LA portions **301/302**. RA/LA portions **301/302** include tubular sections **390** having multiple outward extending members **391**, which in this embodiment are in the shape of flaps **391**. Flaps **391** are preferably configured to engage septal wall **207** and at least partially close PFO tunnel **215**. Flaps **391** can be deflected inwards from the configuration depicted here to lower the overall width **336** of implant **103** and allow the size of delivery device **104** to be minimized.

[0122] This embodiment of implant **103** can be formed by cutting a NITINOL tube with, for instance, a laser or electrical discharge machining (EDM) and the like. FIG. **11B** depicts an exemplary embodiment of a NITINOL tube **393**, with dashed lines **394** indicating the desired cut-lines. After being cut, flaps **391** can be extended outwards and heat treated to instill the desired outward extending shape. Also, coiled segments **306** can be wound to a different width **310** with a different stacking distance **311** as desired using body shaping device **380** in a manner similar to that described with respect to FIGS. **10A-B**. This embodiment of implant **103** can also be pre-processed and post-processed in a manner similar to that described with respect to FIG. **10A** above.

[0123] Turning now to the devices and methods for delivering implant **103**, FIG. **12** depicts another exemplary embodiment of treatment system **100** within heart **200**. Implant **103** is preferably delivered from right atrium **205**, although delivery from left atrium **212** is also possible. Right atrium **205** is preferably accessed via inferior vena cava **202**. In this embodiment, implant **103** is delivered from within delivery device **104**. To facilitate delivery in this manner, longitudinal axis **108** of delivery device **104** is preferably substantially parallel, i.e., at least close to parallel but not necessarily parallel, to the normal **109** of the surface of septal wall **207** into which implant **103** is to be delivered. However, as shown in FIG. **12**, longitudinal axis **108** of delivery device **104** is close to perpendicular to this normal **109** (shown here extending into the page). To accommodate for this, treatment system **100** is preferably configured for off-axis delivery, which allows the orientation of delivery device **104** to be changed so that the longitudinal axis **108** of delivery device **104** is transverse to the longitudinal axis **107** (not shown) of body member **101**.

[0124] FIG. 13 is a block diagram depicting one exemplary embodiment of delivery device 104 configured for off-axis delivery. Here, delivery device 104 includes an off-axis (OA) delivery member 401. Delivery device 104 is preferably configured to grasp or engage cardiac tissue to support and/or facilitate orientation of delivery member 401. Accordingly, an optional tissue engagement device 404 is included within delivery device 104. Delivery device 104 can also include a needle member 405 for puncturing septal wall 207 and a pusher member 406 for pushing implant 103 from within delivery device 104.

[0125] FIG. 14A is a perspective view depicting another exemplary embodiment of treatment system 100, including body member 101, delivery device 104 and stabilization device 105. Here, OA delivery member 401 is an elongate flexible tubular member having open distal end 410. Inner lumen 102 of body member 101 is preferably configured to slidably receive OA delivery member 401, such that OA delivery member 401 can be advanced both proximally and distally. Distal end 410 of OA delivery member 401 is coupled with an elongate support structure 411 of body member 101 via optional grasping device 404. In this embodiment, grasping device 404 includes an arm member 409 coupled with support structure 411 and OA delivery member 401 with hinges 407 and 408, respectively. A biasing element 413 can also be optionally included, to apply a bias force to maintain arm member 409 in the position shown here. Stabilization device 105 is also an elongate member preferably placed in a location to oppose arm member 401.

[0126] FIG. 14B is a cross-sectional view depicting another exemplary embodiment of OA delivery member 401 with embodiments of needle member 405, pusher member 406 and implant 103 located within lumen 414. Needle member 405 has an open distal end 415 and an inner lumen 414 in which pusher member 406 and implant 103 are slidably received and housed. In this embodiment, implant 103 is deformed to the housed configuration where RA/LA portions 301/302 are relatively straightened but central portion 303 remains in the coiled at rest configuration. As will be discussed in more detail below, delivery of implant 103 is accomplished by first orienting delivery device 104 in the desired orientation transverse to longitudinal axis 107 such that distal end 410 is in proximity with septal wall 207, then advancing needle member 405 through septal wall 207 to create opening 315. After needle member 405 has advanced through septal wall 207 into left atrium 212, pusher member 406 is advanced distally to push LA portion 302 of implant 103 from within lumen 414. Once outside lumen 414, LA portion 302 returns to the coiled at rest configuration. Needle member 405 can then be retracted proximally such that LA portion 302 engages septal wall 207 and remains in left atrium 212. As needle member 405 is retracted through septal wall 207, central portion 303 deploys within opening 315. Once needle member 405 is retracted back into lumen 402, OA delivery member 401 can be retracted from septal wall 207 thereby allowing RA portion 301 to deploy and engage septal wall 207 in a coiled configuration.

[0127] FIGS. 14C-F are perspective views depicting a portion of septal wall 207 and an additional exemplary embodiment of treatment system 100 during use of delivery device 104 prior to insertion of needle member 405. Here, the preferred location for insertion of needle member 405 is indicated by location 419. FIG. 14C depicts treatment system 100 with delivery device 104 in the on-axis position, where the

longitudinal axes 107-108 are generally or substantially parallel. Stabilization device 105, the use and structure of which will be described in more detail below, is shown positioned within PFO tunnel 215. In FIG. 14D, OA delivery member 401 has been retreated proximally with respect to body member 101 and in opposition to bias member 413, causing distal end 410 to rotate, or pivot, away from stabilization device 105 by way of arm member 409 and hinges 407-408. In FIG. 14E, treatment system 100 is advanced distally in direction 416 until the underside surface 417 of arm member 409 abuts limbus 211, at which point OA delivery member 401 can be advanced distally with respect to body member 101 to force arm member 409 back towards stabilization device 105 to clamp, or grasp limbus 211 between arm member 409 and stabilization device 105, which is preferably in a substantially fixed position with respect to arm member 409. By grasping limbus 211 in this manner, treatment system is effectively anchored to septal wall 207.

[0128] In FIG. 14F, OA delivery member 401 is further advanced distally with respect to body member 101, which causes OA delivery member 401 to deflect, or arc outwards, in order to rotate distal end 410 about hinge 408 into the desired orientation with respect to septal wall 207. Distal end 410 is now preferably in contact with septal wall 207 at the desired needle insertion location 419. As shown here, OA delivery member 401 is in an outwardly arced state. The degree to which OA delivery member 401 arcs outwards can be adjusted by altering the length of OA delivery member 401 present outside of body member 101. Because needle member 405, pusher member 406 and implant 103 all preferably move within OA delivery member 401, the radius of curvature of the arc is preferably kept large enough to allow movement within OA delivery member 401. A very large rate of curvature can result in sharp angles or kinking in OA delivery member 401 that can make movement difficult.

[0129] As shown in FIG. 14F, longitudinal axis 108, as measured at distal end 410, is now transverse to longitudinal axis 107. Preferably, the delivery angle 417, which is the angle between longitudinal axis 107 and longitudinal axis 108 as measured at distal end 410, is approximately 90 degrees. Once distal end 410 is in the desired orientation, needle member 405 can be advanced into septal wall 207.

[0130] The needle insertion location 419 can be placed in any desired location, but should be chosen based in part on the configuration and size of implant 103 and the degree of overlap between septum primum 214 and septum secundum 210. For instance, in one exemplary embodiment, which is included for illustration only and in no way should be used to limit the invention, needle insertion location 419 is placed between 3 and 7 mm from limbus 211. The position of needle insertion location 419 can be determined by the length of arm member 409, which in turn can position distal end 410 using limbus 211 as a point of reference. To allow for added flexibility, the length of arm member 409 can be configured to be adjustable during the implantation procedure. Thus, arm member 409 is preferably configured for at least two functions: (1) to stop travel of body member 101 at limbus 211 by abutting limbus 211 and (2) to position distal end 410 in the desired needle insertion location 419.

[0131] FIGS. 15A-D are perspective views depicting additional exemplary embodiments of grasping device 404 in a pulled back position. In FIG. 15A, arm member 409 is configured to engage limbus 211 with a contoured undersurface 417 that accommodates the shape of limbus 211 in order to

facilitate grasping or engagement. Undersurface **417** can also be textured as desired to increase surface friction, or made lubricious to assist in friction-free centering, and, as shown here, undersurface can include abutments **420** configured to fixably grasp limbus **211**. Also, it should be noted that any type of hinges **407-408** can be used including, but not limited to, the swivel type hinges depicted here.

[0132] FIGS. **15B-C** depict exemplary embodiments of grasping device **404** where hinges **407** and **408** are integrated into arm member **409**. In FIG. **15B**, arm member **409** includes two elastic wires **420** and **421** each configured to flex at hinge positions **407** and **408**, e.g., by reducing the thickness of the material at the hinge positions. Arm member **409** is preferably biased towards a downwards position, which can allow elimination of any additional biasing element **413**. In FIG. **15C**, arm member **409** is configured to be both flexible and stretchable and can be composed of an elastomeric or rubber-like material or thin or slotted metal. This flexibility and stretchability facilitates the conformance of arm member **409** to limbus **211**. Here, arm member **409** includes tubular portions **422** and **423** for coupling arm member **409** with OA delivery member **401** and support structure **411**, respectively.

[0133] FIG. **15D** is a perspective view depicting yet another exemplary embodiment of grasping device **404**. Here, arm member **409** again includes two flexible wires **420** and **421** that can be coupled with OA delivery member **401**. Like the embodiment described with respect to FIG. **15B**, hinges **407** and **408** can be integrated into wires **420** and **421**, which can be biased towards a downwards position. As shown in FIG. **15D**, wires **420** and **421** are preferably routed through aperture **499** into a lumen **102** within body member **101** and to the proximal end of body member **101**, where they can be independently adjusted to control, or steer, OA delivery member **401**. For instance, distal movement of both wires **420** and **421** moves distal end **410** of OA delivery member **401** distally and proximal movement of both wires **420** and **421** moves distal end **410** of OA delivery member **401** proximally. Distal advancement of wire **420** with respect to wire **421**, alone or in combination with proximal movement of wire **421** with respect to wire **420**, moves distal end **410** in lateral direction **497**, while reverse movement moves distal end **410** in lateral direction **498**.

[0134] FIGS. **16A-B** are cross-sectional views depicting additional exemplary embodiments of treatment system **100** with delivery device **104**. FIG. **16A** depicts a longitudinal cross-sectional view of treatment system **100** and FIG. **16B** depicts a radial cross-sectional view of treatment system **100** taken along line **16B-16B** of FIG. **16A**. Here, delivery device **104** includes a steerable OA delivery member **401**, which is configured to be freely steerable to position distal end **410** in the desired orientation at needle insertion location **419**. Accordingly, distal end **410** is preferably left unconnected with any grasping device **404** (not shown). Preferably, steerability is provided through the use of one or more pull wires **424** coupled with distal end cap **475**. In this embodiment, four pull wires **470-473** are equally spaced apart from each other within lumen **402**. This configuration allows for manipulation of distal end **410** to any three-dimensional (X, Y, Z) orientation. For instance, pulling wire **470** back proximally with respect to wires **471-473**, or pulling wire **472** back proximally with respect to wires **470-471** and **473** allows movement of distal end **410** in the X-Z plane. Pulling wire **471** back proximally with respect to wires **470** and **472-473**, or pulling wire

473 back proximally with respect to wires **470-472** allows movement of distal end **410** in the Y-Z plane.

[0135] FIG. **16C** is a perspective view depicting the embodiment described with respect to FIGS. **16A-B** during delivery. Here, distal end **410** has been oriented in its needle insertion location **419** and longitudinal axis **108** lies within both the X-Z and Y-Z planes. The degree of steerability can be altered as desired for each individual application. For instance, the inclusion of additional pull back wires can provide for more finely controllable steerability, while the deletion of any of pull wires **470-473** can eliminate freedom of steerability, but can simplify the overall design of device **104**. The design and use of steerable devices is also discussed in parent U.S. patent application 10/847,747, filed on May 7, 2004.

[0136] As mentioned above, OA delivery member **401** is preferably configured to allow slidable movement of needle member **405**, pusher member **406** and implant **103** within inner lumen **402**. Preferably, OA delivery member **401** is configured so as to maintain a sufficient degree of structural integrity and kink resistance, while at the same time providing adequate torque or twist control. In one exemplary embodiment, OA delivery member **401** is composed of a flexible braided metal reinforced polymeric tube configured to provide the desired amount of kink resistance and torque control. In another exemplary embodiment, OA delivery member **401** is composed of a metal tube having apertures located therein to provide added flexibility. For instance, OA delivery member **401** can be a NITINOL slotted tube, with the size and spacing of each slot configured for optimal flexibility, kink resistance and torque control. The apertures are preferably placed in a location corresponding to the portion of OA delivery member **401** that extends or arcs out, while the portion of OA delivery member **401** proximal to this can be left solid without apertures to maintain resilience in OA delivery member **401** and provide resistance to push back from needle member **405** as it penetrates septal wall **207**.

[0137] Furthermore, OA delivery member **401** can be coated to provide low friction surfaces to facilitate advancement of OA delivery member **401** within body member **101** and the patient's body, as well as to facilitate movement of needle member **405** within lumen **402**. For instance, FIG. **17** is a cross-sectional view depicting an exemplary embodiment of OA delivery member **401** taken along line **17-17** of FIG. **14A**. Here, OA delivery member **401** includes an inner coating **427** and an outer coating **428**. Coatings **427** and **428** can be any material used to lower surface friction, including, but not limited to polymers such as polytetrafluoroethylene, fluorinated ethylene/propylene copolymers, silicones, hydrogels, hydrophilic coatings or polyurethane (PU) and the like. Preferably, a high density PU material is used that is thin enough to provide the desired degree of flexibility while at the same time providing a low friction surface.

[0138] Like OA delivery member **401**, needle member **405** and pusher member **406** are also preferably flexible elongate members. FIG. **18A** is a cross-sectional view of an exemplary embodiment of needle member **405**. Distal end **415** of needle member **405** is preferably substantially sharp enough to penetrate the desired portion of septal wall **207**. In this embodiment, distal end **415** is tapered similar to a conventional needle. Also, needle member **405** is preferably flexible enough to move within OA delivery member **401** when deflected for off-axis delivery.

[0139] For instance, needle member 405 can include one or more openings, or apertures 436, to increase flexibility. Here, needle member 405 includes multiple apertures 436 in various arrangements. Needle member 405 can be fabricated from any desired material including, but not limited to, NITINOL and stainless steel, and apertures 436 can be formed in any manner including, but not limited to, molding, milling, grinding, laser cutting, EDM, chemical etching, punching and drilling. The design and use of flexible needles is also discussed in parent U.S. patent application 10/847,747, filed on May 7, 2004.

[0140] A first region 437 of needle member 405 includes apertures 436 located at various intervals around the circumference of needle member 405. A second region 438, located distal to the first region 437, includes apertures 436 on the lower portion of needle member 405. FIG. 18B is a cross-sectional view depicting an exemplary embodiment of needle member 405 in a deflected state within an exemplary embodiment of OA delivery member 401. Because apertures 436 in region 437 are located around the circumference of needle member 405, region 437 is relatively more flexible than region 438. In region 438, placement of apertures 436 on the lower surface, reduces the possibility that implant 103 will catch or snag an aperture 436 during advancement of needle member 405 from OA delivery member 401. In addition, distal tip 439 of needle member 405 is also preferably aligned on the lower portion of needle member 405 to reduce the possibility that distal tip 439 will impact, catch, snag, or damage OA delivery member 401.

[0141] Treatment system 100 preferably includes one or more sensors to facilitate determination of when needle member 405 has entered left atrium 212. For instance, in one exemplary embodiment, needle member 405 includes a sensor at or near distal end 415. The sensor can be any type of applicable sensor, such as a pressure sensor, thermal sensor, imaging device, acoustic device and the like. In one exemplary embodiment, a pressure sensor is included that is configured to sense the blood pressure change between right atrium 205 and left atrium 212. The pressure sensor can be any type of pressure sensor including, but not limited to, an electrical sensor and a fluid feedback sensor such as a lumen within needle member 405 having an open distal end in fluid communication with the exterior environment. In an alternative exemplary embodiment, distal end 415 of needle member 405 is configured to be visible by an external imaging device, which can then be used to track the position of distal end 415 with respect to septal wall 207.

[0142] FIG. 18C is a cross-sectional view of another exemplary embodiment of delivery device 104. Here, distal end 440 of pusher member 406 is configured to push against central portion 303 of implant 103 as opposed to end tip 336 of RA portion 301. This reduces the likelihood that RA portion 301 will coil when pushed within lumen 414, which could result in bunching of implant 103 within lumen 414 making delivery more difficult. Because distal end 440 of pusher member 406 is located distal to RA portion 301, pusher member 405 includes a relatively thinner portion 441 that can provide additional room for RA portion 301 within lumen 414 as well as provide added flexibility to pusher member 406. Relatively thinner portion 441 is relatively thinner than distal end 440, which is preferably thick enough to adequately engage central portion 303. Distal end 440 can include a recess 442 to provide enough room for RA portion

301. Distal end surface 443 can be configured in any manner desired to facilitate proper contact and engagement of implant 103.

[0143] For instance, FIGS. 19A-B are cross-sectional views depicting exemplary embodiments of pusher member 406 and implant 103. In FIG. 19A, distal end surface 443 is contoured with a rounded recessed portion 444 into which a coiled central portion 303 can rest and an elevated portion 445 configured to fit within open interior region 327. As one of skill in the art will readily recognize, the contours of distal end surface 443 are dependent on the type and housed configuration of implant 103, as well as the desired point of contact on implant 103. In FIG. 19B, distal end surface 443 is contoured with a narrow recessed portion 446 into which end tip 336 of RA portion 301 can rest.

[0144] Pusher member 406 can also be configured to releasably couple with implant 103. For instance, in one exemplary embodiment, pusher member 406 is tethered to implant 103 with a tether in order to allow implant 103 to be drawn back into needle member 405 if needed, such as in a case of improper deployment. If implant 103 is properly deployed, the tether can be released from pusher member 406. In another exemplary embodiment, pusher member 406 can be configured to both push and pull implant 103 while within needle member 405, as depicted in FIGS. 20A-B.

[0145] FIGS. 20A-B are schematic views depicting additional exemplary embodiments of needle member 405, pusher member 406 and implant 103. In FIG. 20A, implant 103 is placed over outer surface 450 of needle member 405 and end tips 336 of RA portion 301 and LA portion 302 can be routed through apertures 451 and 452, respectively, and housed within lumen 414. To deliver implant 103, after needle member 405 has traversed septal wall 207 into left atrium 212, pusher member 406 is used to pull implant 103 back proximally to expose end tip 336 of LA portion 302 as depicted in FIG. 20B. To grasp end tip 336, pusher member 405 can include any type of grasping device desired. Here, pusher member 406 includes a clamp-type device 453. Once removed from aperture 452, LA portion 302 can enter the coiled state. As needle member 405 is withdrawn back through septal wall 207, LA portion 302 engages septal wall 207 and cause implant 103 to slide off needle member 405. Pusher member 406 can also be used to push end tip 336 of RA portion 301 to facilitate deployment.

[0146] Delivery device 104 can be configured to maintain the proper orientation of OA delivery member 401, needle member 405, pusher member 406 and implant 103 during delivery. FIG. 21 is a cross-sectional view depicting another exemplary embodiment of delivery device 104 taken along lines 21-21 of FIG. 14A where delivery device 104 is configured to use a lock and key technique to maintain proper orientation. Here, the lock and keys are implemented with a combination of abutments and corresponding recesses. For instance, outer surface 450 of needle member 405 includes a recess 456 configured to receive an abutment 455 located on inner surface 457 of OA delivery member 401. Recess 456 can extend longitudinally along needle member 405 for any desired distance to ensure proper orientation even when needle member 405 is advanced and retreated within OA delivery member 401. Similarly, outer surface 458 of pusher member 406 includes a recess 459 configured to receive an abutment 460 located on inner surface 461 of needle member 405. Like recess 456, recess 459 can extend longitudinally along pusher member 406 for any desired distance to ensure

proper orientation when pusher member 405 is advanced and retracted. As discussed above with respect to FIGS. 18A-B, pusher member 406 can include recess 442 to accommodate for the presence of RA portion 301. This recess 442 can also maintain implant 103 in the proper orientation with respect to pusher member 406.

[0147] The distances that OA delivery member 401, needle member 405 and pusher member 406 are moved proximally and distally with respect to body member 101, can be relatively small. Manual movement of these components, while possible, can be difficult. Treatment system 100 can include one or more automated systems or devices at the proximal end of body member 101 to facilitate movement of these components and lessen the risk that each component is inadvertently advanced too far or not enough. The automated systems or devices can also be configured to apply the desired amount of force to move each component and sense if too much force is being used, which could be indicative of an error in the delivery process.

[0148] To further facilitate movement of OA delivery member 401, needle member 405 and pusher member 406, each can be optionally pre-shaped. For instance, in one exemplary embodiment, one or more of OA delivery member 401, needle member 405 and pusher member 406 can include a curved section that corresponds to the desired deflected arc shape of OA delivery member 401 depicted in FIG. 14F.

[0149] As described with respect to FIG. 1, treatment system 100 can optionally include stabilization device 105. FIG. 22 is a block diagram depicting an exemplary embodiment of stabilization device 105 within treatment system 100. Here, stabilization device 105 is preferably configured to stabilize treatment system 100 during delivery of implant 103. Stabilization device 105 can have any configuration desired in accordance with the needs of the application. For instance, stabilization device 105 can be configured as a body routed through PFO tunnel 215 or any portion of the patient's vasculature, such as superior vena cava 203. Stabilization device 105 preferably includes an elongate stabilization member 501 and can optionally include grasping device 502, which is preferably configured to grasp nearby tissue in order to facilitate stabilization.

[0150] FIGS. 23A-C are cross-sectional views depicting additional exemplary embodiments of stabilization device 105 being used to in an exemplary method of stabilizing treatment system 100. Here, stabilization member 105 is configured as an elongate member including an outer tubular sheath 501 having an inner lumen 504 configured to slidably receive inner elongate pull member 505. Outer tubular sheath 501 and inner pull member 505 are preferably semi-rigid, having enough rigidity to stabilize treatment system 100 while at the same time having enough flexibility to allow movement and manipulation within the patient's vasculature and heart 200. In these embodiments, stabilization device 105 is preferably configured to be routed from right atrium 205 through PFO tunnel 215 into left atrium 212, where grasping device 502 can be used to cover a portion of septum primum 214 and anchor stabilization device 105 thereto.

[0151] The nature of the tissue forming septum primum 214 can be irregular, for instance including overlapping folds, variations in tissue thickness and variations in distensibility, each of which can cause septum primum 214 to move, or tent, when needle member 405 is advanced through. The inclusion

of grasping device 502 can also provide the additional advantage of holding septum primum 214 in place and reducing the risk of tenting.

[0152] Grasping device 502 preferably includes a flexible grasping element 506 coupled with inner pull member 505. Here, grasping element 506 is configured as a rectangular element. Outer sheath 501 preferably includes lumen 507 having open distal end 508, from which grasping element 506 can be deployed. Lumen 507 can be configured with contoured sidewalls to facilitate deployment of grasping element 506. To deploy grasping element 506, inner member 505 can be pulled in a proximal direction with respect to outer sheath 501, causing grasping element 506 to advance through lumen 507 and out of distal end 508. Grasping element 506 can optionally include an atraumatic end 512, which in this embodiment is a radio-opaque element, which may be gold or platinum. In this embodiment, grasping element 506 is configured as a deformable, pre-shaped element having three main configurations.

[0153] FIG. 23A depicts grasping element 506 in a first configuration housed within lumen 507. This configuration is preferably used while treatment system 100 is moved through the patient's vasculature and as well as when stabilization device 105 traverses PFO tunnel 215, as depicted here. FIG. 23B depicts grasping element 506 in a second configuration partially deployed from within lumen 507. Once stabilization device 105 is advanced through PFO tunnel 215 and out of PFO exit 218, grasping element 506 is preferably deployed to this configuration by pulling inner member 505 proximally with respect to outer sheath 501. In this configuration, grasping element 506 can be used to catch the edge of septum primum 214 as stabilization device 105 is pulled slightly back in proximal direction 509. FIG. 23C depicts grasping element 506 in a third, fully deployed configuration, after inner member 505 has been pulled back further. Grasping element 506 can optionally include a recess configured to engage an abutment on outer sheath 501 in this configuration, which is preferably used to more fully grasp or engage septum primum 214 to anchor stabilization device 105 thereto.

[0154] Once the delivery procedure is complete, inner member 505 can be advanced distally with respect to outer sheath 501 to draw grasping element 506 back within lumen 507. Any component of treatment system 100 adequately coupled with stabilization device 105 is thereby also anchored to septum primum 214. One of skill in the art will readily recognize that this and similar embodiments of stabilization device 105 can be used to engage any tissue flap or edge desired, not solely septum primum 214.

[0155] Grasping device 502 can be configured in any manner desired in accordance with the needs of the application. FIGS. 24A-B are perspective views depicting additional exemplary embodiments of stabilization device 105 with grasping device 502. In FIG. 24A, grasping device 502 includes multiple grasping elements 506 for grasping over a wider area. In FIG. 24B, grasping device 502 includes a wire-like grasping element 506. Here, grasping element 506 is looped into lumen 507 (not shown) via apertures 510 and 511, which communicate with lumen 507.

[0156] FIGS. 25A-D are cross-sectional views depicting additional exemplary embodiments of stabilization device 105. Here, grasping element 506 has a flap-like shape with tapered inner surface 516 and is located on distal end member 517 of outer sheath 501. Inner member 505 includes an abutment 514 on distal end portion 515 and is configured to push

against and apply a force to grasping element **506**. FIG. **25A** depicts grasping element **506** in the first, housed configuration. To deploy grasping element **506** to the second configuration for catching septum primum **214**, inner member **505** is advanced distally with respect to outer sheath **501** as depicted in FIG. **25B**. Because of tapered inner surface **516**, the more inner member **505** is advanced distally, the more outwards deflection of element **506** will occur. To more fully grasp septum primum **214**, inner member **505** is retreated proximally by the desired amount, as depicted in FIG. **25C**. Manufacture of this embodiment can be made relatively simple. For instance, distal end member **517** and grasping element **506** can be formed by laser or EDM cutting a NITINOL tube. In FIG. **25D**, distal end member **517** is located on distal end of inner member **505** and abutment **514** is located on sheath **501**.

[0157] FIGS. **26A-C** are cross-sectional views of additional exemplary embodiments of stabilization device **105**. Here, outer sheath **501** preferably includes an open distal end **518**, from which grasping device **502** can be deployed. Grasping element **506** is preferably located on distal end portion **515** of inner member **505** and can be formed of a deformable elastic material such as stainless steel, NITINOL, shape memory polymers and the like. Grasping element **506** is preferably configured to be slidable within inner lumen **504** and is preferably pre-shaped, such as by heat-treating NITINOL, so that grasping element **506** can assume a desired shape when advanced from inner lumen **504**. In FIG. **26A**, grasping element **506** is depicted in the first, housed configuration within inner lumen **504**. In FIG. **26B**, inner member **505** has been advanced distally to deploy grasping element **506** in the second configuration for catching septum primum **214**. In FIG. **26C**, inner member **505** has been advanced further distally to place grasping element **506** in the third configuration for grasping septum primum **214**. Embodiments of stabilization device **105** where grasping device **502** can be deployed by pushing device **503** out from within inner lumen **504**, such as that described with respect to FIGS. **26A-C**, will be referred to herein as “push out” embodiments.

[0158] FIG. **27A** is a perspective view depicting an additional exemplary embodiment of stabilization device **105** having a “push-out” grasping device **502**. Here, grasping device **502** is shown in the fully deployed third configuration having two grasping elements **506**. It should be noted that grasping device **502** can include any number of grasping elements **506**. Here, each grasping element **506** overlaps so as to provide additional grasping force. FIG. **27B** is a cross-sectional view depicting another exemplary embodiment where grasping element **506** is configured to attract to a magnetic force **522** provided by magnet **523** coupled with inner member **505**. Once deployed, the magnetic force is preferably great enough to penetrate outer sheath **501** and septum primum **214** and attract elements **506** to provide additional grasping force. Of course, magnet **523** can be placed in any desired location, for instance, on outer sheath **501** or on grasping element **506**, in which case inner member **505** could be configured to attract to the magnetic force.

[0159] It should be noted that, in order to provide additional surface friction, additional abutments can be included on grasping element **506** and/or the surface of grasping element **506** can be etched or coated or otherwise textured.

[0160] As discussed with respect to FIG. **1**, treatment system **100** can include centering device **106** to facilitate proper placement of implant **103**. Centering device **106** can be configured to align delivery device **104** in the desired location

with respect to the center of PFO tunnel **215**. Although the term “centering” is used, it should be understood that device **106** can be configured to align delivery device **106** in any location, not necessarily the center of PFO tunnel **215**.

[0161] FIGS. **28A-C** are cross-sectional views depicting additional exemplary embodiments of centering device **106**. In this embodiment, centering device **106** includes an elongate centering support member **601** having two elongate flexible positioning members **602**, referred to herein as centering arms **602**, located on opposite sides of and extending along the length of support member **601**. Support member **601** can include two lumens **603**, each configured to slidably receive a centering arm **602**. Each lumen **603** preferably has an open distal end **606** which opens to an open or recessed portion **605** of support member **601**. Each centering arm **602** preferably extends through this recessed portion **605** and into seat **604** preferably configured to receive distal end **607** of each centering arm **602**. Seat **604** is preferably located in recessed portion **605** in a position opposite to lumen **603**.

[0162] FIG. **28A** depicts centering arms **602** at rest within recessed portion **605** along the sides of support member **601**. FIG. **28B** is a cross-sectional view of centering device **106** taken along line **28B-28B** of FIG. **28A**. As depicted here, centering arms **602** are preferably configured as rectangular wire bands, although any configuration can be used as desired. Advancement of centering arms **602** in a distal direction causes distal end **607** to contact seat **604** and forces centering arms **602** to extend outwards from recessed portion **605** as depicted in FIG. **28C**. Configuration of centering arms **602** as bands helps ensure that arms **602** extend directly away from support member **601** in direction **611**.

[0163] When centering device **106** is placed within PFO tunnel **215**, centering arms **602** can be extended until coming into contact with sidewalls **219**, as depicted in FIG. **28D**, which is a perspective view of centering device **106** within PFO tunnel **215**. Here, sidewalls **219** and PFO exit **218** are shown as dashed lines to indicate their presence underneath septum secundum **210**. When centering arms **602** are each advanced the same amount until contact with both sidewalls **219** is made, the extension distance **608** of each arm **602** will likewise be the same amount and support member **601** will be forced into a centered position within PFO tunnel **215**.

[0164] In this manner, centering device **106** can be centered within PFO tunnel **215** and can be used as a reference point for delivering implant **103**. Preferably, centering device **106** is coupled with delivery device **104**, so that centering of centering device **106** will also cause centering of delivery device **104**. Preferably, once implant **103** is delivered, centering arms **602** are returned to their original positions and centering device can be retreated through PFO tunnel **215**. Surface **610** of recessed portion **605** is preferably curved, or tapered, to reduce the risk that support member **601** will catch or become hung up on any tissue in or around PFO tunnel **215**.

[0165] Here, the extended portions of centering arms **602** are shown as being located entirely within PFO tunnel **215**. One of skill in the art will readily recognize that variation of length **609** of recessed portion **605** will cause the extended portion of centering arms **602** to vary accordingly.

[0166] Support member **601** and centering arm **602** can each be composed of any desired material in accordance with the needs of the application. Preferably, support member **601** is composed of a flexible polymer, such as polyimides, polyamides, polypropylene and the like. Preferably, centering arms

602 are composed of a flexible polymer or metal, such as NITINOL, stainless steel and the like.

[0167] In the embodiment described with respect to FIGS. 28A-D, centering arms **602** have a curved or arcuate shape when extended from support member **601**. As the FIGS. 29A-C will show, centering arms **602** can be configured to have any desired shape when extended. FIGS. 29A-B are schematic views depicting additional exemplary embodiments of centering device **106** with centering arms **602** extended in a three-sided and two-sided shapes, respectively. Preferably, portions **612** of centering arms **602** are made thinner than the surrounding portions, so that centering arms **602** have a tendency to flex first in portions **612**, allowing these polygonal shapes to be achieved.

[0168] Also, arms **602** can be pre-shaped to be biased to assume a desired shape when allowed to advance from recessed portion **605**. For instance, in one exemplary embodiment, arms **602** are composed of NITINOL and are heat-treated for pre-shaping. One of skill in the art will readily recognize, in light of this disclosure, that variation of the thickness of arms **602** and pre-shaping can allow an almost limitless number of shapes to be achieved, having curved portions, straight portions and any combination thereof which can be symmetric or asymmetric.

[0169] As mentioned above, in some cases, sidewalls **219** of PFO tunnel **215** are not equidistant along the length of PFO tunnel **215**, causing PFO tunnel **215** to diverge or converge from PFO entrance **217** to PFO exit **218**. Divergence or convergence of PFO tunnel **215** can cause centering device **106** to slip out from PFO tunnel **215** when arms **602** are extended. FIG. 29C is a schematic view depicting another exemplary embodiment of centering device **106** where each centering arm **602** is configured to extend with two outcroppings **614**. These outcroppings **614** can be placed outside PFO tunnel **215** to prevent centering device **106** from slipping out of PFO tunnel **215**. Outcroppings **614** can be formed by making that portion of centering arm **602** relatively thicker than the surrounding portions, making outcropping **614** less likely to flex. A desired radius of curvature in centering arms **602** can be implemented by pre-shaping, or by gradually varying the thickness of centering arms **602**, where a relatively thinner portion will correspond to a relatively larger rate of curvature.

[0170] It should be noted that centering device **106** can include any number of one or more arms **602** for centering/positioning purposes. FIG. 30 is a schematic view depicting another exemplary embodiment of centering device **106** having one centering arm **602** extended within PFO tunnel **215**. In this embodiment, PFO tunnel **215** is curved to one side and centering arm **602** is positioned on the opposite side. Centering arm **602** can then be extended a predetermined distance to position centering device **106** in the desired location.

[0171] In some embodiments, it can be desirable to keep centering device **106** within PFO tunnel **215** while needle member **405** is advanced through septal wall **207**. To reduce the risk that needle member **405** will damage centering device **106** during this procedure, support member **601** can be configured to be impact resistant. FIG. 31 is a schematic view depicting an exemplary embodiment of centering device **106** where support member **601** is a rigid cylindrical member **649** having a smooth, or polished, surface **615** between lumen **603** and seat **604** (as shown in FIG. 28A), which are formed in rigid extrusions **650** which are preferable metal and located on member **649**. Here, if sharpened distal end **415** of needle

member **405** comes into contact with support member **601**, it is more likely to be deflected from support member **601**.

[0172] FIGS. 32A-B are cross-sectional views depicting additional exemplary embodiments of centering device **106** where support member **601** includes an open distal end **616** from which one or more pre-shaped centering arms **602** can be extended. Centering arms **602** are preferably pre-shaped to the extended position allowing elimination of seat **604** and recessed portion **605**. Centering arms **602** are preferably deformable from a first configuration to allow housing within inner lumen **617** of support member **601** as depicted in FIG. 32A. In FIG. 32B, centering arms **602** are shown deployed from inner lumen **617** in their extended second configuration. Although in FIGS. 32A-B, centering arms **602** are shown as separate elements, the proximal end of the pre-shaped portion of each arm **602** can be coupled together on a common elongate shaft.

[0173] It should be noted that the functionality of the various embodiments described herein can be combined and integrated together to reduce the number of components in treatment system **100**, simplify the design of treatment system **100** and so forth. For instance, FIG. 32C depicts an exemplary embodiment of treatment system **100** where the embodiments described with respect to FIGS. 27A and 32A-B have been integrated together to form device **110**. Here, centering arms **602**, similar to that depicted in FIGS. 32A-B each include grasping element **506** of stabilization device **105**, similar to that depicted in FIG. 27A, located distal to the centering portion **618**. Here, centering device **106** is used for centering and stabilization, allowing the elimination of a separate stabilization device **105** from system **100**.

[0174] For stabilization and centering, support member **601** is preferably advanced through PFO exit **218**. Once in left atrium **212**, centering arms **602** can be advanced distally to deploy grasping elements **506** from the first, housed configuration, to the second and third configurations for catching and grasping septum primum **214**. Once septum primum **214** is grasped, support member **601** can be retreated proximally with respect to centering arms **602** in order to deploy centering portions **618** of each arm **602**. The centering portions **618** can then expand outwards and center device **106**, while at the same time maintaining a grasp of septum primum **214**.

[0175] FIG. 32D is a schematic view depicting another exemplary embodiment of treatment system **100** where centering device **106** and stabilization device **105** have been integrated together. Here, stabilization member **501** includes two lumens **603** and seats **604** (not shown), and recessed portions **605** for use with centering arms **602**. After stabilization with device **105**, centering arms **602** can be extended in directions **611** to center or otherwise place combined device **110** in the desired position.

[0176] As discussed with respect to FIG. 1, delivery device **104**, stabilization device **105** and centering device **106** are each preferably used in conjunction with body member **101**. Body member **101** can be configured in any manner desired in accordance with the needs of the application. FIGS. 33A-B are cross-sectional views depicting another exemplary embodiment of treatment system **100** where body member **101** includes two lumens **630** and **631**. FIG. 33A is a longitudinal cross-sectional view and FIG. 33B is a radial cross-sectional view taken along line 33B-33B of FIG. 33A. Preferably, lumen **630** is configured to slidably receive delivery device **104**, while lumen **631** is configured to slidably receive either stabilization device **105** or an optional guidewire to

facilitate routing body member 101 through the patient's vasculature. The guidewire can be placed in lumen 631 until body member 101 is in the desired position within the patient, at which time the guidewire can be removed and stabilization device 105 can be inserted. Also, centering device 106 is preferably integrated with stabilization device 105, such as in the embodiment described with respect to FIG. 32D, in order to provide treatment system with both stabilization and centering capability. In order to prevent rotation of elongate body member 101 around stabilization device 105 during delivery, stabilization device is preferably fixably coupled with either body member 101 or delivery device 104.

[0177] FIGS. 34A-C are cross-sectional views depicting another exemplary embodiment of treatment system 100 where body member 101 includes four lumens 630-633 as well as centering arms 602. Here, FIG. 34A is a first longitudinal cross-sectional view, FIG. 34B is a radial cross-sectional view taken along line 34B-34B of FIG. 34A and FIG. 34C is a second longitudinal cross-sectional view taken along line 34C-34C of FIG. 34A. Preferably, lumen 630 is configured to slidably receive delivery device 104, while lumen 631 is configured for any purpose, including reception of stabilization device 105, a guidewire, dye infusion and the like. FIG. 34B depicts centering arms 602 within lumens 632-633 and FIG. 34C depicts centering arms 602 located within lumens 632-633, recessed portions 605 and seats 604. Here, recessed portions 605 and seats 604 are located distal to grasping device 404 on elongate support section 411. The distal portion of support section 411 can be placed within PFO tunnel 215 where centering arms 602 can be deflected for centering prior to deployment of implant 103 in left atrium.

[0178] FIGS. 35A-B are cross-sectional views depicting another exemplary embodiment of treatment system 100 where body member 101 includes three lumens 630, 632 and 633 as well as centering arms 602. Here, FIG. 35A is a longitudinal cross-sectional view and FIG. 35B is a radial cross-sectional view taken along line 35B-35B of FIG. 35A. In this embodiment, distal end 410 of body member 101 includes an atraumatic tip 640, which in this embodiment is a floppy tip. Here, with the aid of atraumatic tip 640, body member 101 is configured to be advanceable within the patient's vasculature without the aid of a guidewire. Accordingly, no additional lumen 631 is included for use with a guidewire. Also in this embodiment, stabilization device 105 has been optionally omitted, allowing body member 101 to achieve a relatively smaller radial cross-section size. In another exemplary embodiment, atraumatic tip 640 is omitted and body member 101 is configured to be slidably advanced through a tubular guide catheter placed within the patient's vasculature.

[0179] FIGS. 36A-B are cross-sectional views depicting another exemplary embodiment of treatment system 100 where body member 101 includes four lumens 630-633 as well as centering arms 602. Here, FIG. 36A is a longitudinal cross-sectional view and FIG. 36B is a radial cross-sectional view taken along line 36B-36B of FIG. 36A. This embodiment is similar to the embodiment described with respect to FIGS. 34A-C except here, lumen 631 is configured for use with guidewire 641 only, which can be relatively thinner than stabilization device 105, allowing the radial cross-section size of lumen 631 and body member 101 to be reduced.

[0180] FIGS. 37A-B are cross-sectional views depicting another exemplary embodiment of treatment system 100 where body member 101 includes four lumens 630-633 as

well as centering arms 602. Here, FIG. 37A is a longitudinal cross-sectional view and FIG. 37B is a radial cross-sectional view taken along line 37B-37B of FIG. 37A. This embodiment is similar to the embodiment described with respect to FIGS. 35A-C except here, lumen 631 is configured to facilitate exchange of stabilization device 105 and guidewire 641. Proximal portion 642 of lumen 631 includes a divider 643 to separate lumen 631 into a first portion 644 for stabilization device 105 and a second portion 645 for guidewire 641. Distal portion 646 of lumen 631 is preferably tapered to minimize the radial cross-section size of lumen 631. Exchange between stabilization device 105 and guidewire 641 is facilitated because both can reside within proximal portion 642 at the same time, with the desired one of stabilization device 105 or guidewire 641 being advanced distally through open distal end 647 for use.

[0181] It should be noted that in each of the embodiments described with respect to FIGS. 33A-37B, functionality can be added or removed as desired, while still remaining within the scope of treatment system 100. For instance, treatment system 100 can be further configured for dye infusion, pressure sensing, imaging, drug delivery, ablation, the use of occlusive devices such as balloons and stents, coronary sinus application of pacing or defibrillation leads, the use of a stylet and the like. These and other additional types of functionality can be added in any manner, including, but not limited to the addition of one or more lumens 102, or the use of the existing lumens 102, integration directly into body member 101, or the addition of one or more extra body members 101.

[0182] In addition, treatment system 100 can include multiple delivery devices 104 for delivery of multiple implants 103, multiple stabilization devices 105 for stabilization on multiple tissue surfaces, multiple centering devices 106 and multiple body members 101 as desired. If treatment system 100 is used to access septal wall 207 via inferior vena cava 202, the maximum radial cross-section size of body member 101 is preferably 13 french or less, although it should be noted that any size body member 101 can be used in accordance with the needs of the application. Body member 101 can be constructed from any material as desired, but is preferably constructed from a flexible polymer such as polyethylene, polypropylene, nylon and the like.

[0183] Furthermore, it should be noted that any component or component portion within treatment system 100 can be configured to facilitate any type of imaging, including, but not limited to, internal and external ultrasound imaging, optical imaging, magnetic resonance imaging (MRI), and fluoroscopy. For instance, OA delivery member 401 can be entirely radio-opaque, or can include portions that are radio-opaque, such as on distal tip 430 of FIG. 14A.

[0184] Also described herein are methods 700 and 800 of treating PFO tunnel 215, preferably by at least partially closing PFO tunnel 215. Methods 700 and 800 are preferably used with treatment system 100, but can be used with any medical system as desired. For ease of discussion, method 700 will be described with respect to treatment system 100 and method 800 will be described without reference to a particular treatment system, although it should be understood that methods 700 and 800 can be used with or without treatment system 100. Generally, the steps of methods 700 will vary, in part, on the actual configuration of implant 103, the number of implants 103 to be delivered, the location in which each

implant 103 is to be delivered, the use of guidewire 641 or a guide catheter and the optional use of stabilization device 105 and/or centering device 106.

[0185] In FIG. 4E, implant 103 is delivered through both septum primum 214 and septum secundum 210. It should be noted, however, that implant 103 can be delivered in any location desired. FIGS. 38A-C are cross-sectional views of septal wall 207 depicting exemplary embodiments of implant 103 in just several of the many alternate locations that can be used. In FIG. 38A, implant 103 has been delivered through the upper portion of septum secundum 210 adjacent to PFO exit 218. In FIG. 38B, implant 103 has been delivered through the lower portion of septum primum 214, adjacent to PFO entrance 217 and near (or in) fossa ovalis 208. In FIG. 38C, implant 103 has been delivered through septal wall 207 adjacent to sidewall 219, septum primum 214 and septum secundum 210.

[0186] Also, as many implants 103 can be used in any arrangement as desired. FIGS. 38D-E are views of septal wall 207 depicting exemplary embodiments of multiple implants 103 in just several of the many alternate arrangements that can be used. In FIG. 38D, three implants 103 have been delivered through both septum primum 214 and septum secundum 210. In FIG. 38E, six implants 103 have been delivered through septal wall 207 adjacent to both sidewalls 219, septum primum 214 and septum secundum 210.

[0187] Although there are many different implementations and variations of method 700, for ease of discussion, method 700 will be described herein as using one implant 103, delivered through both septum primum 214 and septum secundum 210, using an exemplary embodiment of treatment system 100 similar to that described above with respect to FIGS. 33A-B, where body member 101 is configured for use with stabilization device 105 having centering device 106 integrated thereon.

[0188] FIGS. 39A-B are flow diagrams depicting an example of method 700. First, at 701, body member 101 is placed in proximity with PFO region 209. As mentioned above, implant 103 can be delivered from left atrium 212 or right atrium 205. Preferably, implant 103 is placed into proximity with PFO region 209 by advancing body member 101 from the femoral vein to right atrium 205 in a conventional manner. For instance, in one example, a needle is inserted into the femoral vein and a guidewire is advanced through the needle into the femoral vein. The needle can then be removed and an access sheath can be routed over the guidewire, which can also then be removed. A J-tip guidewire, such as a 0.035"/0.038" guidewire, can be routed through the patient's vasculature into inferior vena cava 202 and right atrium 205. From there, the guidewire can be routed through PFO tunnel 215 and into left atrium 212. Next, an exchange sheath or multi-purpose guide can then be advanced over the J-tip guidewire into left atrium 212, at which point the J-tip guidewire can be removed. A relatively stiffer guidewire 641 can then be advanced through the exchange sheath or multi-purpose guide and into left atrium 212 and optionally the pulmonary vein, which can act as an anchor for the guidewire. Body member 101 can then be advanced over the guidewire 641 into proximity with PFO region 209, preferably through PFO tunnel 215 and into left atrium 212. In addition, a catheter or guidewire having a sizing device, such as a balloon, can be placed within PFO tunnel 215 to measure the size of PFO tunnel 215, for use in choosing a placement location, implant size, etc.

[0189] At 702, guidewire 641, if present, can be removed. At 704, stabilization device 105 is preferably advanced through lumen 631 and into left atrium 212. At 706, body member 101 can be retreated proximally into right atrium 205. Preferably, stabilization device 105 includes a stabilization member 501 and grasping device 502 with grasping element 506. At 708, grasping element 506 can be deployed from the first housed configuration to the second configuration for catching tissue, which, in this example, is preferably septum primum 214.

[0190] Next, at 710, stabilization member 501 is preferably moved distally until grasping element 506 catches septum primum 214. Then, at 712, OA delivery member 401 can be retracted proximally with respect to body member 101 to raise arm member 409. At 714, body member 101 and OA delivery member 401 are advanced distally until arm member 409 abuts limbus 211. At 716, centering device 106 can be used to center delivery device 101, preferably by deflecting centering arms 602. Once centered, if not already done so, at 717 stabilization device 105 can be fixably coupled to delivery device 104 (e.g., with a rotating hemostasis valve or Tuohy-Borst valve and the like). Next, at 718, grasping element 506 can be further deployed to the third configuration to grasp septum primum 214 and lock stabilization device 105 to septum primum 214. Alternatively, either 716, 717, 718 or any combination thereof can be implemented prior to 712. Also, 716-718 can be implemented in any order desired with respect to each other.

[0191] Once stabilized, centered and locked in place, OA delivery member 401 is preferably advanced distally with respect to body member 101 to rotate distal end 410 into the desired orientation with surface 320 of septum secundum 210. At 722, needle member 405 can be advanced through septum secundum 210 and septum primum 214 and into left atrium 212. Then, at 724, pusher member 406 can be advanced distally to at least partially deploy LA portion 302 of implant 103 from distal end 415 of needle member 405. In embodiments where centering arms 602 are in their deflected state for centering, it is possible for needle member 405 to pass between centering arms 602 and stabilization member 501 when inserted, based on needle insertion location 419. To avoid capture of implant 103 between centering arms 602 and stabilization member 501, centering arms 602 can be retracted proximally back into elongate body 101 thereby removing them from seats 604 and preventing implant 103 from being trapped between centering arms 602 and stabilization member 501. Next, at 726, grasping element 506 can be moved to the second configuration to free stabilization device 105 from septum primum 214. Alternatively, 726 can be performed before 724 if desired.

[0192] Then, at 728, LA portion 302 can be fully deployed if not already. At 730, grasping element 506 can be removed to the first configuration, housed within stabilization member 501. Next, at 732, centering device 106 can be undeployed if not already, preferably by collapsing centering arms 602, after which stabilization device 105 can be retreated proximally from PFO entrance 217 at 734. At 736, needle member 405 can be withdrawn into OA delivery member 401 to deploy central portion 303 of implant 103 and at least a portion of RA portion 301. Here, at 738, an optional closure test can be performed to confirm at least partial closure, and preferably substantially complete closure, of PFO tunnel 215. Any desired closure test can be performed including, but not limited to, the introduction of gaseous bubbles simulta-

neously with imaging using contrast enhanced trans-cranial doppler (CE-TCD), intracardiac echocardiography (ICE) and the like. The test may be performed by pulling back OA delivery member **401** as far as it will move to deploy RA coil **301** and then test while device is at PFO entrance.

[0193] If the desired degree of closure is confirmed, then any tether connection to implant **103** can be released at **740**. At **742**, OA delivery member **401** can be retracted proximally with respect to body member **101** to complete deployment of RA portion **301**, release limbus **211** and place OA delivery member **401** in the original position. Finally, at **744**, body member **101** can be retracted distally and withdrawn from the patient.

[0194] FIG. 40 depicts another exemplary method **800** of treating a septal defect. At **802**, limbus **211** is abutted with an abutment of a medical device. Preferably, limbus **211** is engaged with the medical device and optionally grasped such that the medical device is anchored to limbus **211**. Then, at **804**, a hole in septal wall **207**, preferably in septum secundum **210**, is created using limbus **211** as a point of reference. For instance, the hole can be created at a fixed or adjustable distance from limbus **211**. At **806**, the hole is used to facilitate delivery of a device configured to treat a septal defect. In one example, the device is deployed through the hole such that it causes at least partial closure of the septal defect. In this example of method **800**, limbus **211** is abutted and used as a reference. In another example of method **800**, the edge of septum primum **214** is abutted and used as a reference. In other examples of method **800**, one or both sidewalls **219** and/or fossa ovalis **208** are abutted and used as points of reference.

[0195] It should be noted that any feature, function, method or component of any embodiment described with respect to FIGS. 1-40 can be used in combination with any other embodiment, whether or not described herein. As one of skill in the art will readily recognize, treatment system **100** and the methods for treating a septal defect can be configured or altered in an almost limitless number of ways, the many combinations and variations of which cannot be practically described herein.

[0196] The devices and methods herein may be used in any part of the body, in order to treat a variety of disease states. Of particular interest are applications within hollow organs including but not limited to the heart and blood vessels (arterial and venous), lungs and air passageways, digestive organs (esophagus, stomach, intestines, biliary tree, etc.). The devices and methods will also find use within the genitourinary tract in such areas as the bladder, urethra, ureters, and other areas.

[0197] Furthermore, the off-axis delivery systems may be used to pierce tissue and delivery medication, fillers, toxins, and the like in order to offer benefit to a patient. For instance, the device could be used to deliver bulking agent such as collagen, pyrolytic carbon beads, and/or various polymers to the urethra to treat urinary incontinence and other urologic

conditions or to the lower esophagus/upper stomach to treat gastroesophageal reflux disease. Alternatively, the devices could be used to deliver drug or other agent to a preferred location or preferred depth within an organ. For example, various medications could be administered into the superficial or deeper areas of the esophagus to treat Barrett's esophagus, or into the heart to promote angiogenesis or myogenesis. Alternatively, the off-axis system can be useful in taking biopsies, both within the lumen and deep to the lumen. For example, the system could be used to take bronchoscopic biopsy specimens of lymph nodes that are located outside of the bronchial tree or flexible endoscopic biopsy specimens that are located outside the gastrointestinal tract. The above list is not meant to limit the scope of the invention.

[0198] In some embodiments, the off-axis delivery system is used with an anchoring means in order to anchor the device to a location within the body prior to rotation of the off-axis system. This anchoring means may involve the use of a tissue grasper or forceps. It should be noted that any device or set of devices can be advanced within the lumen of the off-axis delivery system, including but not limited to needles, biopsy forceps, aspiration catheters, drug infusion devices, brushes, stents, balloon catheters, drainage catheters, and the like.

[0199] While the invention is susceptible to various modifications and alternative forms, a specific example thereof has been shown in the drawings and is herein described in detail. It should be understood, however, that the invention is not to be limited to the particular form disclosed, but to the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit of the disclosure.

What is claimed is:

1. In an implantable apparatus having a longitudinal axis for deploying an implantable closure member through the septum walls of a patent foramen ovale, the improvement comprising:

- a needle adapted to pierce the septum secundum and the septum primum of a patent foramen ovale, said needle having a lumen,
- a housing having a lumen which houses said needle,
- a grasper adapted to grasp the limbus of the septum secundum and to alter the orientation of the distal end of said housing relative to the longitudinal axis of the apparatus, said needle housing a closure member in the lumen therein, said closure member having a body comprising a first end portion, a second end portion and a central portion located therebetween, the first end portion being configured to engage a first outer septal surface of the septum primum, the second end portion being configured to engage a second outer septal surface of the septum secundum and the central portion being configured to fit within an opening in the septal walls formed by said needle that traverses a septal defect tunnel, at least one of said portions being coiled.

* * * * *